Catalysts / SXTP
Upcoming FDA decisions and readouts we track for 60 Degrees Pharmaceuticals, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for 60 Degrees Pharmaceuticals (SXTP, listed on Nasdaq). It concerns Tafenoquine (Babesiosis (interim analysis)).
First on the list: the Clinical readout for Tafenoquine (Babesiosis (interim analysis)), dated 06 Oct 2026, which has passed without an outcome recorded here yet, so check the source and the company's latest filings.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| 60 Degrees Pharmaceuticals SXTP · Nasdaq | Tafenoquine | Babesiosis (interim analysis) | 06 Oct 2026 1d ago |
Clinical readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList